Fig. 1From: A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritisPatient disposition. AE, adverse event; b.i.d., twice daily; t.i.d., three times dailyBack to article page